Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Sep 13, 2021Subgroup analyses from registrational Phase 3 KEYNOTE-775/Study 309 and CLEAR/KEYNOTE-581 trials provide additional data on KEYTRUDA (pembrolizumab) plus LENVIMA (lenvatinib)Eisai Inc. announced today the presentation of 13 abstracts across multiple types of cancer from its oncology portfolio during the upcoming European Society for Medical Oncology (ESMO) Congress...
Aug 11, 2021KEYTRUDA Plus LENVIMA Is Now Approved for Two Types of Cancer, Including Advanced RCCKENILWORTH, N.J., and WOODCLIFF LAKE, N.J., Aug. 11, 2021 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced that the U.S. Food and Drug...
Jul 22, 2021Immunotherapy and Tyrosine Kinase Inhibitor Combination Approved for the Treatment of Patients With Advanced Endometrial Carcinoma That is Not Microsatellite Instability-High or Mismatch Repair Deficient, Who Have Disease Progression Following Prior Systemic Therapy in Any Setting and Are Not Candidates for Curative Surgery or RadiationKENILWORTH, N.J., and WOODCLIFF LAKE, N.J., July 22, 2021 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai Inc. today announced that the U.S. Food and Drug...
Jun 18, 2021TOKYO AND NEW YORK, June 18, 2021 -- Eisai Co., Ltd. and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the companies have entered into an exclusive global strategic collaboration...
Jun 7, 2021Results From New Analysis Evaluating Health-Related Quality of Life (HRQoL) Based on Patient-Reported Outcomes Using Three HRQoL ScalesKENILWORTH, N.J., and WOODCLIFF LAKE, N.J., June 7, 2021 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai Inc. today announced new investigational data from the...
May 18, 2021- Data include landmark median progression-free survival (PFS), overall survival (OS) and objective response rate (ORR) in patients, including those with triple-negative breast cancer (TNBC)Eisai today announced results from a real-world study assessing treatment patterns and clinical outcomes with HALAVEN® (eribulin mesylate) injection as a third-line therapy or greater in patients...
-
May 17, 2021Eisai to present more than 25 abstracts including investigational data on oncology pipeline and products
Eisai Inc. announced today the presentation of more than 25 abstracts across various types of cancer from its oncology portfolio during the virtual scientific program of the 2021 American Society...
-
May 6, 2021Applications Based on Progression-Free Survival, Overall Survival, and Objective Response Rate Data From Respective Pivotal Phase 3 Trials
KENILWORTH, N.J., and WOODCLIFF LAKE, N.J., May 6, 2021 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai Inc. today announced that the U.S. Food and Drug...
-
Apr 29, 2021
Eisai announced today that the European Journal of Cancer published the results from a post hoc analysis of the Phase 3 SELECT study evaluating the impact of lung metastases on overall survival...
Mar 31, 2021Endometrial Cancer Is on the Rise, Yet Under-Recognized. Black Health Matters, FORCE, SHARE and Eisai Partner to Inspire Women to Listen, Advocate and Put Their Health FirstEisai Inc. announced today the launch of Spot Her—an initiative to end the silence around endometrial cancer, a type of uterine cancer, and inspire women to listen, advocate and put their health...